Episode Details
Back to EpisodesCLL at ASH 2025: Time Limited Triplet, Timing of Anti-CD20 Therapy, and GAIA/CLL13
Episode 648
Published 2 months, 3 weeks ago
Description
Drs. Wierda and O’Brien discuss new combination treatments for CLL that achieve exceptionally high rates of undetectable disease, especially with triplet regimens. They also show that venetoclax-based retreatment works very well, supporting a move away from chemoimmunotherapy.